Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30117% above fair value

$26.24−0.23 (-0.87%)

Close on Nov 13, 2026Market cap $1.86BP/E 50.5Yield –

Zymeworks price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Zymeworks's price to sales ratio was 55.9× on Nov 11, 2026, against 14.9× a year earlier. Over the last 5 years it ranged from 1.0× to 56.6×, with a median of 11.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	55.9×	+41.2
2025	Dec 31, 2025	14.7×	−1.7
2024	Dec 31, 2024	16.4×	+14.8
2023	Dec 29, 2023	1.5×	−14.7
2022	Dec 30, 2022	16.2×	−5.0
2021	Dec 31, 2021	21.2×	–